Third-generation oral contraceptives and thromboembolism risk

Obstetrics and Gynecology

Volumn 89, Issue 6, 1997, Pages 1028-1030

  Poindexter, Alfred N ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 0030915566     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00132-4     Document Type: Article

References (13)

1. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD, on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. BMJ 1996;312:83-8.
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
3. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-82.
4. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
5. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346: 1593-6.
6. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M, on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of myocardial infarction: An international case-control study. BMJ 1996;312:88-90.
7. Lewis MA, Heinemann LAJ, MacRae RD, Brupacher R, Spitzer WO. Increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research. Contraception 1996;54:5-13.
8. Westhoff CL. Oral contraceptives and venous thromboembolism: Should epidemiologic associations drive clinical decision making? Contraception 1996;54:1-3.
9. Lidegaard O, Milsom I. Oral contraceptives and thrombotic disease: Impact of new epidemiological studies. Contraception 1996; 53:135-9.
10. McPherson K. Third generation oral contraception and venous thromboembolism. BMJ 1996;312:68-9.
11. Rosenberg L, Begaud B, Bergman V, Brown B, Buist AS, Cramer D, et al. What are the risks of third-generation oral contraceptives? Hum Reprod 1996;11:687-8.
12. Weiss N. Third generation oral contraceptives: How risky? Lancet 1995;346:1570.
13. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993;81:1034-47.